Liraglutide and Glycaemic Outcomes in the LEADER Trial

INTRODUCTION: The LEADER trial was a cardiovascular (CV) outcomes trial in patients with type 2 diabetes at high CV risk that compared liraglutide (n = 4668) with placebo (n = 4672) using a primary composite endpoint of 3-point major adverse CV events. The objective of this post hoc analysis was to...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Diabetes Ther
Main Authors: Zinman, Bernard, Nauck, Michael A., Bosch-Traberg, Heidrun, Frimer-Larsen, Helle, Ørsted, David D., Buse, John B.
Format: Artigo
Sprog:Inglês
Udgivet: Springer Healthcare 2018
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6250637/
https://ncbi.nlm.nih.gov/pubmed/30392095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0524-z
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker